These long-term data support axicabtagene ciloleucel as a highly effective therapeutic approach for patients with relapsed or ...

In a retrospective cohort of patients with central nervous system manifestations of multiple myeloma, ide-cel CAR T-cell ...

In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear ...

Pirtobrutinib, a third-generation BTK inhibitor, showed superior progression-free survival and lower treatment ...

Initial therapy with sonrotoclax and zanubrutinib showed strong efficacy and acceptable safety in untreated CLL/SLL.

Ira Zackon, MD, discusses the real-world uptake of bispecific antibodies in community oncology practices and what it reveals about their utilization in relapsed/refractory multiple myeloma treatment.

Elizabeth A. Brem, MD, an assistant clinical professor in the Division of Hematology/Oncology, School of Medicine at the University of California, Irvine, discusses multiple types of therapies used in ...

A phase 3 trial of uproleselan in relapsed/refractory acute myeloid leukemia failed to meet the primary overall survival end ...

The 48-week end points of the MANIFEST-2 study show improvements in spleen reduction, symptoms, bone marrow fibrosis, and ...

Long-term data from the pivotal phase 3 ELARA trial showed durable efficacy with tisagenlecleucel in high-risk follicular ...

Julio Chavez, MD, MS, discusses some of the important studies and research being presented at the 2024 American Society of ...

Capivasertib combination shows promise in mHSPC vs the placebo combination, LBS-007 received fast track designation, and RP1 plus nivolumab submitted a BLA application. We also cover a retrospective ...